Literature DB >> 34597394

Prospective Cohort Study of Pre- and Postdiagnosis Obesity and Endometrial Cancer Survival.

Renée L Kokts-Porietis1, Jessica McNeil2, Andria R Morielli1, Linda S Cook3,4, Kerry S Courneya5, Christine M Friedenreich1,4,6.   

Abstract

BACKGROUND: Disease-free survival (DFS) and overall survival (OS) associations with anthropometric measures of obesity and changes in these exposures remain unknown among endometrial cancer survivors.
METHODS: Endometrial cancer survivors diagnosed between 2002 and 2006 completed direct anthropometric measurements and self-reported lifetime weight history during in-person interviews approximately 4 months after diagnosis (peridiagnosis) and approximately 3 years after diagnosis (follow-up). Participants were followed-up until death or March 20, 2019. Cox proportional regression was used to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for body mass index (BMI), weight, waist circumference, and waist-hip ratio with DFS and OS. Statistical tests were 2-sided.
RESULTS: A total of 540 and 425 cancer survivors were assessed peridiagnosis and follow-up, respectively. During the median 14.2 years of follow-up (range = 0.3-16.5 years), 132 participants had a recurrence and/or died (DFS), with 111 deaths overall (OS). Reduced DFS was noted with greater recalled weight 1 year before diagnosis (HR = 1.88, 95% CI = 1.15 to 3.07), BMI 1 year before diagnosis (HR = 1.88, 95% CI = 1.09 to 3.22), and measured peridiagnosis BMI (HR = 2.04, 95% CI = 1.18 to 3.53). Measured peridiagnosis waist circumference of at least 88 cm was associated with decreased DFS (HR = 1.94, 95% CI = 1.24 to 3.03) and OS (HR = 1.90, 95% CI = 1.16 to 3.13). A twofold decrease in DFS and OS was associated with a BMI of at least 5% or weight change from 1 year before diagnosis to peridiagnosis. No associations were observed for the assessment during follow-up.
CONCLUSIONS: One-year before- and peridiagnosis anthropometric measures of obesity were associated with reduced survival among endometrial cancer survivors. Anthropometric changes from 1 year before to peridiagnosis may provide an important indication of future survival in this population.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2022        PMID: 34597394      PMCID: PMC8902344          DOI: 10.1093/jnci/djab197

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   11.816


  34 in total

1.  Prospective cohort study of metabolic syndrome and endometrial cancer survival.

Authors:  Renée L Kokts-Porietis; Jessica McNeil; Gregg Nelson; Kerry S Courneya; Linda S Cook; Christine M Friedenreich
Journal:  Gynecol Oncol       Date:  2020-06-27       Impact factor: 5.482

2.  Adaptation and evaluation of the National Cancer Institute's Diet History Questionnaire and nutrient database for Canadian populations.

Authors:  Ilona Csizmadi; Lisa Kahle; Ruth Ullman; Ursula Dawe; Thea Palmer Zimmerman; Christine M Friedenreich; Heather Bryant; Amy F Subar
Journal:  Public Health Nutr       Date:  2007-01       Impact factor: 4.022

3.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

4.  Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients.

Authors:  Hannah Arem; Yikyung Park; Colleen Pelser; Rachel Ballard-Barbash; Melinda L Irwin; Albert Hollenbeck; Gretchen L Gierach; Louise A Brinton; Ruth M Pfeiffer; Charles E Matthews
Journal:  J Natl Cancer Inst       Date:  2013-01-07       Impact factor: 13.506

Review 5.  Change in body size and mortality: a systematic review and meta-analysis.

Authors:  Amalia Karahalios; Dallas R English; Julie A Simpson
Journal:  Int J Epidemiol       Date:  2017-04-01       Impact factor: 7.196

6.  Body weight changes after the diagnosis of endometrial cancer and their influences on disease-related prognosis.

Authors:  Samer El-Safadi; Anna Sauerbier; Andreas Hackethal; Karsten Münstedt
Journal:  Arch Gynecol Obstet       Date:  2012-01-19       Impact factor: 2.344

7.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

8.  The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study.

Authors:  Sarah J Kitson; Jennifer Lindsay; Vanitha N Sivalingam; Mark Lunt; Neil A J Ryan; Richard J Edmondson; Martin K Rutter; Emma J Crosbie
Journal:  Gynecol Oncol       Date:  2017-11-24       Impact factor: 5.482

9.  Weight change across adulthood in relation to all cause and cause specific mortality: prospective cohort study.

Authors:  Chen Chen; Yi Ye; Yanbo Zhang; Xiong-Fei Pan; An Pan
Journal:  BMJ       Date:  2019-10-16

10.  Prospective Cohort Study of Pre- and Postdiagnosis Physical Activity and Endometrial Cancer Survival.

Authors:  Christine M Friedenreich; Linda S Cook; Qinggang Wang; Renée L Kokts-Porietis; Jessica McNeil; Charlotte Ryder-Burbidge; Kerry S Courneya
Journal:  J Clin Oncol       Date:  2020-10-07       Impact factor: 44.544

View more
  1 in total

1.  Associations of insulin resistance and inflammatory biomarkers with endometrial cancer survival: The Alberta endometrial cancer cohort study.

Authors:  Andria R Morielli; Renée L Kokts-Porietis; Jamie L Benham; Jessica McNeil; Linda S Cook; Kerry S Courneya; Christine M Friedenreich
Journal:  Cancer Med       Date:  2022-02-16       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.